View : 978 Download: 0
A Model for Adaptive Decision Making of 'Ablate-and-Wait' Versus Transplantation in Patients with Hepatocellular Carcinoma
- Title
- A Model for Adaptive Decision Making of 'Ablate-and-Wait' Versus Transplantation in Patients with Hepatocellular Carcinoma
- Authors
- Kim H.Y.; Kim W.; Jung Y.J.; Lee J.-H.; Yu S.J.; Kim Y.J.; Yoon J.-H.; Lee H.W.; Kim H.; Yi N.-J.; Lee K.-W.; Suh K.-S.
- Ewha Authors
- 김희영; 김휘영
- SCOPUS Author ID
- 김휘영
- Issue Date
- 2018
- Journal Title
- Journal of Clinical Gastroenterology
- ISSN
- 0192-0790
- Citation
- Journal of Clinical Gastroenterology vol. 52, no. 7, pp. 655 - 661
- Keywords
- clinical decision making; hepatocellular carcinoma; transplantation
- Publisher
- Lippincott Williams and Wilkins
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background/Aims: In patients with early-stage hepatocellular carcinoma (HCC), selection of candidates for liver transplantation (LT) requires refinement based on tumor biology to maximize the outcome. We aimed to prognosticate LT candidates with HCC using a risk prediction model for post-LT recurrence. Patients and Methods: A total of 197 consecutive patients were included who underwent LT for hepatitis B-related HCC within the Milan criteria. A risk prediction model was developed for post-LT recurrence using the Cox model and was internally validated. Results: Among those undergoing LT as their first HCC treatment (n=70, initial LT group), poor prognosis was associated with maximal tumor size and multinodularity. The remaining 127 patients (deferred LT group) received radiofrequency ablation (n=69) and/or transarterial chemoembolization (n=98) before LT. Multinodularity, maximal tumor size, posttransarterial chemoembolization progressive disease, baseline alpha-fetoprotein, and alpha-fetoprotein difference (between baseline and pre-LT) were incorporated into a risk prediction model for the deferred LT group, which was thereby stratified into low-risk (score<5), intermediate-risk, and high-risk (score?8) subgroups. Recurrence-free survival was significantly different among the deferred LT prognostic subgroups (P<0.001). Conclusions: This risk prediction model may help refinement of ablate-and-wait strategy for LT candidates by avoiding LT in those with either high risk score at baseline or increasing score under repeated locoregional therapies. © 2017 Wolters Kluwer Health, Inc. All rights reserved.
- DOI
- 10.1097/MCG.0000000000000981
- Appears in Collections:
- 연구기관 > 의과학연구소 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML